{"entity":{"id":"nct07032077","kind":"trial","name":"A Clinical Trial of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors","aka":[],"tldr":"A phase 2 trial of HRS-7058 in advanced solid tumours, run by Shandong Suncadia Medicine Co., Ltd., now recruiting.","summary":"A Clinical Trial of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors is a phase 2 interventional study registered as NCT07032077 by Shandong Suncadia Medicine Co., Ltd., with 100 participants planned, started 2025-07-09 and due to reach its primary completion in 2027-06. Interventions recorded: HRS-7058.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07032077","url":"https://clinicaltrials.gov/study/NCT07032077"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07032077","phase":"2","setting":"A Phase II Clinical Trial on the Safety, Tolerability, and Efficacy of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors","sponsor":"Shandong Suncadia Medicine Co., Ltd.","enrolled":100,"outcomes":[]},"route":"/trials/nct07032077/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}